Results 41 to 50 of about 1,192,795 (361)
An update on non-pharmacological interventions for pain relief
Cell Reports MedicineSummary: Chronic pain affects a substantial portion of the population, yet current treatments often fail to provide adequate relief. Non-pharmacological interventions, which target behaviors and brain processes underlying the experience of pain, hold ...
Yang Wang +3 more
doaj +1 more source
Placebo and Non-specific Effects in Reconsolidation-Based Treatment for Arachnophobia
Frontiers in Psychiatry, 2021 The idea that maladaptive memories may be rendered susceptible to interference after reactivation raises the possibility of reactivating and neutralizing clinically-relevant emotional memories.
James W. B. Elsey, Merel Kindt
doaj +1 more source
Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund +3 more
wiley +1 more source
Dentistry and Medical ResearchContext: Pericoronitis is the soft-tissue inflammation surrounding the dental crown in a semi-erupted lower third molar. Patients with early-stage pericoronitis experience discomfort, redness, swelling, mucosal ulceration, and loss of function.
Shubhamoy Ghosh +8 more
doaj +1 more source
Frontiers in Human Neuroscience, 2016 In their innovative study, Inzlicht and Al-Khindi (2012) demonstrated that participants who were allowed to misattribute their arousal and negative affect induced by errors to a placebo beverage had a reduced error-related negativity (ERN/Ne) compared to
Carmen Cano Rodilla +2 more
doaj +1 more source
Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders
Frontiers in Psychiatry, 2020 Much has been written about the placebo effects in functional gastrointestinal disorders (FGD), especially in irritable bowel syndrome (IBS), driven by the early hypothesis that in randomized controlled trials (RCTs) of IBS, the placebo effect might be ...
Paul Enck, Sibylle Klosterhalfen
doaj +1 more source
Mediterranean Journal of Clinical Psychology, 2022 Background: Nonadherence to homework assignments is a frequent problem among patients with depression during cognitive-behavioral therapy (CBT). The present study investigated the effects of two additional treatment components of CBT: a placebo and SMS ...
Nina Jurinec, Anne Schienle
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo +9 more
wiley +1 more source
Development and Psychometric Evaluation of the Hope in Medicine Scale
Clinical Psychology in Europe[Background] Hope is an integral, multi-dimensional part of seeking medical treatment. The aim of this study was to develop a self-report scale, the Hope in Medicine (HIM) scale, to measure different modes of hoping in relation to the course of symptoms,
Lea Balthasar +4 more
doaj +1 more source
Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies [PDF]
, 2017 Background The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.
Araya, V. +11 more
core +2 more sources